M. Vilarino-Varela

Gene and pathway level analyses of germline DNA-repair gene variants and prostate cancer susceptibility using the iCOGS-genotyping array

J. R. Wilson, David M. Holden, P. W. Foster, 2016, British Journal of Cancer.

Molecular therapy as primary treatment for adult solid cancers: Gefitinib and Imatinib

A. Kong, M. Vilarino-Varela, 2004 .

AIDS-related cancer

M. Spittle, M. Vilarino-Varela, 2001 .

Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol

Warren C. Grant, M. Parmar, M. Sydes, 2021, The Lancet.

Treatment outcomes for small cell carcinoma of the bladder: results from a UK patient retrospective cohort study.

R. Huddart, V. Khoo, N. Vasudev, 2021, International journal of radiation oncology, biology, physics.

Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial

G. Rodrigues, J. Staffurth, T. Tsakiridis, 2019, The Lancet. Oncology.

Benefits of online in vivo dosimetry for single-fraction total body irradiation.

D. Eaton, C. Collis, M. Vilarino-Varela, 2014, Medical dosimetry : official journal of the American Association of Medical Dosimetrists.

A verification study of proposed pelvic lymph node localisation guidelines using nanoparticle-enhanced magnetic resonance imaging.

R. Reznek, A. Rockall, Maria J Vilarino-Varela, 2008, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

VICTOR: Vinflunine (Vin) in advanced metastatic transitional cell carcinoma of the urothelium (TCCU)--A retrospective analysis of use of Vin in multicenter, real life setting as second-line chemotherapy (ChT) through free-of charge-programme (FOCP) for patients (pts) in the UK.

R. Huddart, R. Jackson, G. Faust, 2015 .

Addition of nintedanib or placebo to neoadjuvant gemcitabine and cisplatin in locally advanced muscle-invasive bladder cancer (NEOBLADE): a double-blind, randomised, phase 2 trial.

R. Huddart, T. Powles, N. James, 2022, The Lancet. Oncology.

Current indications for post-mastectomy radiation

A. Makris, Y. Chin, M. Vilarino-Varela, 2009, International seminars in surgical oncology : ISSO.